Last kr264.40 DKK
Change Today -8.00 / -2.94%
Volume 328.4K
NZYMB On Other Exchanges
As of 8:12 AM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

novozymes a/s-b shares (NZYMB) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/22/14 - kr283.60
52 Week Low
12/6/13 - kr204.40
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NOVOZYMES A/S-B SHARES (NZYMB)

Related News

No related news articles were found.

novozymes a/s-b shares (NZYMB) Related Businessweek News

No Related Businessweek News Found

novozymes a/s-b shares (NZYMB) Details

Novozymes A/S produces and sells industrial enzymes, microorganisms, and biopolymers worldwide. The company offers solutions for the agriculture industry, including enzymes to enhance digestibility and nutritional value of animal feed; microbial solutions to maintain water quality, limit risks of disease, and enhance yields in aquaculture; and microbial-based biofertility, biocontrol, and bioyield enhancer products to naturally produce healthier crops and enhance yields. It also provides a portfolio of enzymes for application in biofuel production; recombinant products and technologies to the medical device and drug delivery market; and food and beverages enzymes for applications in baking, brewing, dairy, distilling, flavor enhancement, food specialties, health and nutrition, juice, meat processing, oils and fats, starch, and wine industries. In addition, the company offers household care enzyme and microbial agents for use in cleaning solutions, dishwashing, and laundry; enzymes for biopreparation, degreasing, and re-bating of leather; enzymes for pulp and paper production processes, such as bleach boosting, deinking, drainage enhancement, effluent control, pitch control, refining, slime control, starch modification, and stickies control; enzymatic solutions for processing textiles; and microbial solutions for biological wastewater treatment. Novozymes A/S has a strategic alliance with Monsanto Company to discover, develop, and sell microbial solutions for farmers. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.

6,314 Employees
Last Reported Date: 10/23/14
Founded in 1925

novozymes a/s-b shares (NZYMB) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: kr8.3M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: kr5.2M
Executive Vice President of Supply Operations
Total Annual Compensation: kr5.2M
CSO and Executive Vice President of Research ...
Total Annual Compensation: kr5.0M
Executive Vice President of Business Operatio...
Total Annual Compensation: kr3.6M
Compensation as of Fiscal Year 2013.

novozymes a/s-b shares (NZYMB) Key Developments

Novozymes A/S Presents at UBS European Conference 2014, Nov-11-2014 12:30 PM

Novozymes A/S Presents at UBS European Conference 2014, Nov-11-2014 12:30 PM. Venue: London, United Kingdom. Speakers: Thomas Videbaek, Executive Vice President of Business Development.

Novozymes A/S Announces Unaudited Group Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for 2014

Novozymes A/S announced unaudited group earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, revenue was DKK 3,184 million against DKK 2,936 million a year ago. Operating profit/EBIT was DKK 831 million against DKK 755 million a year ago. Profit before tax was DKK 828 million against DKK 711 million a year ago. Net profit attributable to the company’s shareholders was DKK 639 million or DKK 2.03 per diluted share against DKK 568 million or DKK 1.79 per diluted share a year ago. EBITDA was DKK 1,078 million against DKK 940 million a year ago. For the nine months, revenue was DKK 9,278 million against DKK 8,806 million a year ago. Operating profit/EBIT was DKK 2,541 million against DKK 2,198 million a year ago. Profit before tax was DKK 2,497 million against DKK 2,052 million a year ago. Net profit attributable to the company’s shareholders was DKK 1,923 million or DKK 6.08 per diluted share against DKK 1,639 million or DKK 5.17 per diluted share a year ago. Cash flow from operating activities was DKK 4,255 million, up from DKK 1,793 million in the first nine months of 2013. The higher operating cash flow was mainly a result of The BioAg Alliance agreement coupled with a favorable development in net working capital and higher net profit. Purchase of property, plant and equipment was DKK 355 million against DKK 548 million a year ago. Return on equity was 23.1% against 21.7% a year ago. Negative net interest-bearing debt was DKK 1,354 million at September 30, 2014 against net interest-bearing debt of DKK 1,354 million at September 30, 2013. EBITDA was DKK 3,256 million against DKK 2,750 million a year ago. The full-year 2014 organic sales growth outlook is narrowed in at the middle of the previous range to 7%-8% from 6%-9%. Full-year expectations for EBIT growth are increased to 14%-15% and for net profit growth to 13%-14%, both up from 9%-11%. The EBIT margin is now expected at 26%-27%, up from around 26%. Expectations for ROIC, including goodwill, are increased to 22%- 23%, up from 22%. Lastly, expectations for free cash flow are revised upward by DKK 400 million-DKK 500 million to negative free cash flow before acquisition of DKK 4,300 million, due to expectations of higher profit, lower CAPEX and a lower net working capital ratio.

Novozymes A/S Presents at Consumer Ingredients Conference, Nov-25-2014

Novozymes A/S Presents at Consumer Ingredients Conference, Nov-25-2014 . Venue: .P. Morgan, 25 Bank Street, Canary Wharf, E14 5JP, London, United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NZYMB:DC kr264.40 DKK -8.00

NZYMB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Chr Hansen Holding A/S kr254.20 DKK -4.70
Ebro Foods SA €14.49 EUR -0.095
EMS-Chemie Holding AG SFr.358.25 CHF -3.00
Kerry Group PLC €59.84 EUR +1.14
Sensient Technologies Corp $59.48 USD +0.30
View Industry Companies

Industry Analysis


Industry Average

Valuation NZYMB Industry Range
Price/Earnings 34.2x
Price/Sales 6.8x
Price/Book 7.5x
Price/Cash Flow 28.8x
TEV/Sales 5.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVOZYMES A/S-B SHARES, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at